ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Adicet Bio Inc

Adicet Bio Inc (ACET)

2.35
0.02
(0.86%)
Closed March 29 04:00PM
2.33
-0.02
(-0.85%)
After Hours: 07:43PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.33
Bid
2.32
Ask
2.35
Volume
534,078
2.31 Day's Range 2.395
1.10 52 Week Range 7.50
Market Cap
Previous Close
2.33
Open
2.33
Last Trade Time
Financial Volume
$ 1,256,995
VWAP
2.3536
Average Volume (3m)
1,873,955
Shares Outstanding
43,164,522
Dividend Yield
-
PE Ratio
-1.41
Earnings Per Share (EPS)
-1.62
Revenue
24.99M
Net Profit
-69.79M

About Adicet Bio Inc

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like ant... Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Adicet Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACET. The last closing price for Adicet Bio was $2.33. Over the last year, Adicet Bio shares have traded in a share price range of $ 1.10 to $ 7.50.

Adicet Bio currently has 43,164,522 shares outstanding. The market capitalization of Adicet Bio is $98.42 million. Adicet Bio has a price to earnings ratio (PE ratio) of -1.41.

ACET Latest News

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application (IND) for ADI-001; initiation of Phase 1...

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio Inc. (Name of...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.198.87850467292.142.3952.029502132.16284511CS
4-0.05-2.100840336132.382.541.8815352002.21462826CS
120.3316.523.771.8818739552.69804846CS
260.8860.68965517241.453.771.110903862.43912984CS
52-3.56-60.4414261465.897.51.18829872.80274546CS
156-10.77-82.21374045813.121.871.16367418.38114539CS
2602.17431396.467565830.155721.870.13065823728.22457807CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

ACET Discussion

View Posts
Monksdream Monksdream 6 months ago
ACET new 52 week low
👍️0
Monksdream Monksdream 6 months ago
ACET new 52 week
👍️0
Monksdream Monksdream 6 months ago
ACET new 52 week low
👍️0
jondoeuk jondoeuk 6 months ago
Upcoming https://www.businesswire.com/news/home/20230927031162/en/Adicet-Bio-to-Present-Three-Scientific-Posters-Highlighting-its-Allogeneic-Gamma-Delta-T-Cell-Platform-and-Programs-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting
👍️0
jondoeuk jondoeuk 9 months ago
Durability was always the big question for $ACET. Yesterday's dataset vs #ASH22 above https://t.co/PNIL1N2eUF— Jacob Plieth (@JacobPlieth) June 27, 2023
👍️0
masterofdisaster masterofdisaster 2 years ago
No sell off...guess I bet wrong
👍️0
TheFinalCD TheFinalCD 2 years ago
Phase 1's usually suck wind, I lost $80K on another one,

BIG lesson learned


👍️0
masterofdisaster masterofdisaster 2 years ago
It was weird....I think the MMs drop this at open to begin the sell off today.
👍️0
TheFinalCD TheFinalCD 2 years ago
whats weird is the rally after the offering


this market is upside down

topsy turvey

👍️0
masterofdisaster masterofdisaster 2 years ago
Bought puts today anticipating an offering and there it is.
👍️0
TheFinalCD TheFinalCD 2 years ago
13.20 low start

ACET
👍️0
crudeoil24 crudeoil24 2 years ago
14.20 in AH. Nice day for the clinical FDA phase I trial results.
👍️0
TheFinalCD TheFinalCD 2 years ago
thanks for creating the board

I was too lazy, did I say lazy, I meant bizy

https://ih.advfn.com/stock-market/NASDAQ/adicet-bio-ACET/stock-news/86734727/adicet-posts-early-stage-data-for-off-the-shelf-ca
👍️0
crudeoil24 crudeoil24 2 years ago
Adicet Bio shares are trading higher after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001.
👍️0
crudeoil24 crudeoil24 2 years ago
Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.
👍️0

Your Recent History

Delayed Upgrade Clock